Cleveland Diagnostics' IsoPSA gets NCCN prostate cancer listing

2019 10 16 20 31 7121 Cancer Cells Prostate 400

Cleveland Diagnostics' IsoPSA prostate cancer test is now included in the National Comprehensive Cancer Network's (NCCN) guidelines for early prostate cancer detection.

The guidelines now suggest use of IsoPSA to categorize probability of high-grade prostate cancer (i.e., Gleason score equal to or greater than 3+4, and group grade of 2 or higher) before a first biopsy or after a negative biopsy, the company said.

IsoPSA is a blood-based prostate cancer test that has shown better diagnostic accuracy than prostate-specific antigen (PSA) testing, according to Cleveland Diagnostics.

Page 1 of 6
Next Page